Determination of L-tetrahydropalmatine in human plasma by HPLC and pharmacokinetics of its disintegrating tablets in healthy Chinese.

The objective of the study was to establish an HPLC method for the determination of L: -tetrahydropalmatine in human plasma, and to investigate the pharmacokinetics after oral administration of L: -tetrahydropalmatine disintegrating tablets in healthy Chinese. L: -tetrahydropalmatine in human plasma was separated on a Phenomenex luna C(18) column (250 mm × 4.6 mm, 5 μm), eluted using methanol-water (75:25, v/v) as mobile phase, and detected by photodiode array detector at a wavelength of 281 nm.

[Phase II multicenter clinical trial of nedaplatin in the treatment of malignant tumors].

Objective: To evaluate and compare the efficacy and safety of Nedaplatin (NDP)-based regimen and cisplatin (DDP)-based regimen for head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC), esophageal cancer and ovary epithelial cell carcinoma.

Methods: Single agent group: NDP was administered at a dose of 100 mg/m(2) on D1, every 3 weeks for at least 2 cycles. Combination chemotherapy group: combined with 5-Fu, NVB, VDS + 5-Fu, PTX or CTX respectively, NDP 80 mg/m(2) on D1 or DDP 30 mg/m(2) on D1-3, every 3 weeks for at least 2 cycles was given.